Results 71 to 80 of about 755,013 (356)

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

The clinical predictors of intrauterine fetal death

The Turkish Journal of Pediatrics, 1998
Five hundred and thirteen (513) patients with intrauterine fetal death managed between 1983 and 1990 at Hacettepe University Hospital were analyzed retrospectively. Fetal death rate was 20.5/1,000 deliveries during the study period.
L Onderoğlu, Z S Tuncer
doaj  

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

INCIDENCIA Y FACTORES DE RIESGO ASOCIADOS AL ÓBITO FETAL EN 2 HOSPITALES VENEZOLANOS

Revista Chilena de Obstetricia y Ginecología, 2006
Objetivo: Evaluar la incidencia y factores de riesgo de óbito fetal en una población de embarazadas venezolanas. Metodología: estudio efectuado en 100 mujeres con diagnóstico de óbito fetal que acudieron al servicio de emergencia obstétrica de dos ...
Erika Rojas, Karimar Salas, Gustavo Oviedo, Geovanny Plenzyk   +3 more
doaj  

Autoimmune lymphoproliferative syndrome in pregnancy: a case of favorable mother - fetal outcome in a well-controlled disease [PDF]

, 2014
The autoimmune lymphoproliferative syndrome(ALPS)is a disorder of abnormal lymphocyte survival caused by the dysregulation of theFasapoptotic pathway. The Fas geneis expressed at the maternal–fetal interface and is involved in the regulation of immune ...
Baek, Bleesing, Canale, Ciarmela, Correia-da-Silvia, Ferguson, Fuks, Hansford, Jerzak, Kwak-Kim, Lev, Oliveira, Rao, Rogers, Worth   +14 more
core   +1 more source

ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
In SMAD4‐positive pancreatic ductal adenocarcinoma (PDAC), integrin subunit alpha V (ITGAV) activates latent TGF‐β, which binds to the TGF‐β receptor and phosphorylates SMAD2/3. The activated SMAD2/3 forms a complex with SMAD4, and together they translocate to the nucleus, modulating gene expression to promote proliferation, migration, and invasion. In
Daniel K. C. Lee, Keyue Chen, Ryan Loke, Xiang Li, David Liubart, Golam T. Saffi, Jonathan T. S. Chow, Ché M. P. Melo, Lydia To, Leonardo Salmena   +9 more
wiley   +1 more source

Impacts of COVID-19 on Pregnancy Outcomes: A Retrospective Study

Emergency Care and Medicine
Background: This study compared outcomes of pregnant females with and without COVID-19 and their fetuses/newborns. Methods: This is a retrospective study from 2020 to 2023 utilizing the United States Collaborative Network of the TriNetX Database.
Donna Mendez, Krishna Paul, Jerome L. Yaklic, Dietrich Jehle   +3 more
doaj   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Factores de riesgo prenatales en la muerte fetal tardía, Hospital Civil de Guadalajara, México

Revista Chilena de Obstetricia y Ginecología, 2011
Objetivo: Identificar los factores de riesgo sociodemográficos, obstétricos y perinatales que con más frecuencia se asocian a muerte fetal en embarazos mayores de 27 semanas.
J. Guadalupe Panduro B, J. Jesús Pérez M, Elizabeth Guadalupe Panduro M, Juan Francisco Castro H, María Dolores Vázquez G   +4 more
doaj